A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called "BRAF V600" * received required prior treatment for cancer per cohort assigned. All participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day. Participants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 1, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-07799544; Drug: PF-07799933
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Phase 1b
- Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
- Measurable disease by RECIST version 1.1
- Evidence of a BRAF V600 mutation
- Prior therapy per tumor cohort
- Adequate organ function per protocol Phase 1b
- Other active malignancy within 3 years
- Presence of leptomeningeal disease
- History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease
- Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
- Active gastrointestinal disease as defined per protocol
- History of interstitial lung disease as defined per protocol
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- The Kirklin Clinic of UAB HospitalBirmingham, Alabama
- The University of Alabama at BirminghamBirmingham, Alabama
- University of Alabama at Birmingham - Phase I Clinical Trials UnitBirmingham, Alabama
- Highlands Oncology Group, PAFayetteville, Arkansas
- Highlands Oncology Group, PARogers, Arkansas
- Highlands Oncology Group, PASpringdale, Arkansas
- The Angeles Clinic and Research Institute- A Cedars-Sinai AffiliateLos Angeles, California
- Keck Hospital of USCLos Angeles, California
- Los Angeles General Medical CenterLos Angeles, California
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- Keck Medical Center of USC PasadenaPasadena, California
- UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 1, 2026. Always confirm current availability with the study team.